These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37218715)

  • 1. An overview of the management of osteoporosis in the aging female population.
    Amin U; McPartland A; O'Sullivan M; Silke C
    Womens Health (Lond); 2023; 19():17455057231176655. PubMed ID: 37218715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis.
    Thal KA; Nudy M; Moser EM; Foy AJ
    J Am Board Fam Med; 2023 Feb; 36(1):175-185. PubMed ID: 36653115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.
    Reginster JY
    Drugs; 2011 Jan; 71(1):65-78. PubMed ID: 21175240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of osteoporosis.
    Palacios S
    Climacteric; 2022 Feb; 25(1):43-49. PubMed ID: 34382489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab: mechanism of action and clinical outcomes.
    Hanley DA; Adachi JD; Bell A; Brown V
    Int J Clin Pract; 2012 Dec; 66(12):1139-46. PubMed ID: 22967310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
    Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
    J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis.
    Compston JE; McClung MR; Leslie WD
    Lancet; 2019 Jan; 393(10169):364-376. PubMed ID: 30696576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.
    Shen Y; Gray DL; Martinez DS
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):193-206. PubMed ID: 28131133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
    Ishtiaq S; Fogelman I; Hampson G
    J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis.
    Fan G; Zhao Q; Lu P; Chen H; Tan W; Guo W; Liu C; Liu J
    Medicine (Baltimore); 2020 Apr; 99(15):e18964. PubMed ID: 32282692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoanabolic therapy for osteoporosis in women.
    McClung MR; Clark AL
    Climacteric; 2022 Feb; 25(1):60-66. PubMed ID: 34342243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on osteoporosis treatment.
    Nogués X; Martinez-Laguna D
    Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Osteoporosis Therapies in Combination.
    McClung MR
    Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
    Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
    Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
    Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
    Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.